BCAL Diagnostics Partners With US Pathology Giant to Validate Breast Cancer Test
BCAL Diagnostics signs validation agreement with Sonic Healthcare USA for BreastestPlus Version 2.0
BCAL Diagnostics Limited (ASX: BDX) has executed a Validation Agreement with Sonic Healthcare USA, the third largest pathology provider in the United States, for its flagship BreastestPlus Version 2 breast cancer diagnostic. The agreement positions the test for potential commercialisation in a market recording more than 40 million mammograms annually, 376,000 new breast cancer cases each year, and a breast cancer diagnostics market projected to reach USD 4.53 billion by 2033.
This milestone advances BCAL’s US commercialisation strategy, with the Laboratory Developed Test (LDT) pathway now active. Successful validation would open the door to commercial licence negotiations with Sonic Healthcare USA, though a confirmed commercial arrangement has not yet been reached.
When big ASX news breaks, our subscribers know first
What the agreement means and how the LDT pathway works
Inside the validation process
Under the Validation Agreement, the BreastestPlus Version 2 assay will be transferred to and optimised at Sonic’s CLIA-certified Sonic Reference Laboratory in Austin, Texas. The financial terms of the Validation Agreement are confidential and no commercial figures have been disclosed.
Simultaneously, BCAL is actively collecting clinical samples from US patients, working directly with leading breast cancer specialists. These samples will support Clinical Outcomes studies, which are a requirement for future submissions to regulatory, reimbursement, and health insurance authorities.
Why the LDT pathway is BCAL’s fastest route to US patients
A Laboratory Developed Test (LDT) is a diagnostic test that is developed, validated, and performed within a single CLIA-certified laboratory. This structure means the test does not require the longer pre-market approval process administered by the US Food and Drug Administration (FDA), making it the fastest and most efficient market entry route for BreastestPlus Version 2, as stated in the announcement.
Following successful validation, Sonic Healthcare USA has the option to negotiate a commercial licence for BreastestPlus Version 2 and any related intellectual property and know-how required to use or perform the test. For investors, this represents a clear commercial trigger: successful validation unlocks the pathway to licence negotiations with one of the largest pathology operators in the United States.
The LDT pathway steps, in sequence, are:
- Validation Agreement signed (current stage)
- Assay transfer and optimisation at CLIA-certified Sonic Reference Laboratory in Austin, Texas
- Rigorous validation process conducted by Sonic Healthcare USA
- Successful validation grants Sonic the option to negotiate a commercial licence
- Commercial deployment of BreastestPlus Version 2 to US patients
Sonic Healthcare USA — the right partner at the right scale
As the third largest pathology provider in the United States, Sonic Healthcare USA brings both credibility and infrastructure scale to the validation process. Its CLIA-certified Sonic Reference Laboratory in Austin, Texas provides the regulatory-grade environment required to conduct a rigorous and recognised validation of the BreastestPlus Version 2 assay.
The table below contextualises the US market opportunity and the significance of the partnership:
| Metric | Figure | Source Context | Relevance to BDX |
|---|---|---|---|
| Annual mammograms (US) | 40 million+ | ASX Announcement | Addressable screening base |
| New breast cancer cases (annual, US) | 376,000 | ASX Announcement | Diagnostic demand driver |
| US breast cancer diagnostic market (2033 projection) | USD 4.53 billion | ASX Announcement | Commercial opportunity scale |
| Sonic Healthcare USA ranking | 3rd largest US pathology provider | ASX Announcement | Partner credibility and infrastructure |
Shane Ryan, Chief Executive Officer, BCAL Diagnostics
“This Validation Agreement with Sonic Healthcare USA is an important milestone for BCAL Diagnostics and our US commercialisation strategy. Sonic’s CLIA-certified laboratory infrastructure and deep expertise in clinical diagnostics provide the right environment to validate BreastestPlus™ Version 2. What excites me most is what this brings together — two highly capable teams, united by a shared purpose of delivering better diagnostic solutions for women at scale. We look forward to progressing through the validation process and advancing towards commercial deployment in the world’s largest breast cancer diagnostics market.”
Dr Mohamed Salama, Chief Medical Officer, Sonic Healthcare USA
“Sonic Healthcare USA is committed to advancing access to innovative diagnostic solutions that make a real difference to patients. The validation of BreastestPlus™ Version 2 at our CLIA-certified Sonic Reference Laboratory in Austin, Texas reflects that commitment, and we look forward to assessing its performance through a rigorous validation process.”
The next major ASX story will hit our subscribers first
What comes next for BCAL’s US strategy
Two parallel workstreams are now underway. The first is the Sonic validation process itself, with the BreastestPlus Version 2 assay being transferred and optimised at the Austin laboratory ahead of formal validation. The second is the ongoing US clinical sample collection programme, conducted in collaboration with leading breast cancer specialists.
The clinical samples collected will directly feed BCAL’s Clinical Outcomes studies, a requirement for future submissions to regulatory, reimbursement, and health insurance authorities. In this respect, BCAL is building multiple components of its US market access strategy concurrently rather than sequentially.
Successful validation remains the central near-term catalyst. It represents a key milestone on the LDT pathway and would open the door to commercial licence negotiations with Sonic Healthcare USA. BCAL’s stated objective is to establish BreastestPlus Version 2 as a Laboratory Developed Test in the United States, though the timing and outcome of the validation process have not been confirmed.
Key milestones to watch:
- Completion of assay transfer and optimisation at the Sonic Reference Laboratory in Austin, Texas
- Outcome of Sonic Healthcare USA’s rigorous validation process
- Progress of the Clinical Outcomes study programme
- Potential commercial licence negotiation with Sonic Healthcare USA
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, with in-depth analysis already completed. Join 20,000+ subscribers who stay ahead of market-moving announcements the moment they drop. Click the “Free Alerts” button at StockWire X to start receiving real-time coverage today.